Gerard Sutton, Gordon Wallace, JingJing You, Hannah Frazer8, Simon Cooper8, Chris Hodge
Introduction: Corneal ulceration is a common debilitating condition that accounts for 55,000 pre- sentations to Accident and Emergency in Australia each year. Furthermore it can be complicated by infection and in extreme cases cornel melting lead- ing to severe visual loss. Current treatments include contact lenses, antibiotics and commercial glue for severe cases. The Corneal BioPen is a unique deliv- ery system that allows in situ printing of multiple corneal layers that can be modifted depending on the clinical situation and can seal wounds, promote healing and reduce scarring.
Methods: In collaboration with University of Wol- longong Intelligent Polymer Research Institute (IPRI) we have modifted their orthopaedic BioPen for use on the cornea. Meanwhile, we have devel- oped a customised BioInk that can promote corneal epithelialisation. A collagen crosslinking device has been added to the Biopen delivery system.
Results: The Biopen is capable of delivering the BioInk. The BioInk can be modifted to adjust its constituency and mechanical properties including strength. It is a transparent liquid at room tempera- ture but solidiftes at body temperature. in vitro test- ing conftrms the promotion of cell migration and stratiftcation. The bioink bio-degradable.
Conclusions: The Corneal BioPen is a novel treat- ment for precision, customised treatment of corneal ulceration. It has the potential to improve accelerate healing, reduce risk of infection, reduce hospital admissions, improve health outcomes and reduce corneal/ donor pressure.
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY